Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Sunshine Biopharma logo
$1.41 -0.03 (-2.08%)
Closing price 08/1/2025 03:58 PM Eastern
Extended Trading
$1.41 0.00 (-0.07%)
As of 08/1/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Key Stats

Today's Range
$1.35
$1.44
50-Day Range
$1.41
$1.70
52-Week Range
$1.17
$5.40
Volume
62,221 shs
Average Volume
82,065 shs
Market Capitalization
$6.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Sunshine Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

SBFM MarketRank™: 

Sunshine Biopharma scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sunshine Biopharma has received no research coverage in the past 90 days.

  • Read more about Sunshine Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sunshine Biopharma has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sunshine Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    6.72% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently increased by 241.41%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sunshine Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sunshine Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.72% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently increased by 241.41%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

  • Percentage Held by Institutions

    41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sunshine Biopharma's insider trading history.
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBFM Stock News Headlines

Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift
Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.
SBFM - Sunshine Biopharma Inc News - Morningstar
Sunshine Biopharma, Inc. (SBFM) - Yahoo Finance
Sunshine Biopharma launches Everolimus in Canada
See More Headlines

SBFM Stock Analysis - Frequently Asked Questions

Sunshine Biopharma's stock was trading at $3.00 on January 1st, 2025. Since then, SBFM shares have decreased by 53.0% and is now trading at $1.41.

Sunshine Biopharma, Inc. (NASDAQ:SBFM) released its earnings results on Thursday, May, 15th. The company reported ($0.44) earnings per share for the quarter. The company had revenue of $8.90 million for the quarter. Sunshine Biopharma had a negative net margin of 13.88% and a negative trailing twelve-month return on equity of 21.25%.

Shares of Sunshine Biopharma reverse split on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
8/01/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SBFM
CIK
1402328
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+963.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($150.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.13 million
Net Margins
-13.88%
Pretax Margin
-14.70%
Return on Equity
-21.25%
Return on Assets
-16.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.25
Quick Ratio
2.19

Sales & Book Value

Annual Sales
$36.23 million
Price / Sales
0.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.10 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
4,556,000
Free Float
4,551,000
Market Cap
$6.42 million
Optionable
Not Optionable
Beta
1.44

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SBFM) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners